Head & Neck/Thyroid Cancers
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
From the Journals
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
Conference Coverage
Neoadjuvant immunotherapy shows promise for resectable CSCC
Response to treatment may lead to a reduction in potentially disfiguring surgeries.
News
FDA OKs selpercatinib for adults with RET-fusion+ solid tumors
In 2020, selpercatinib received accelerated approval for lung and thyroid RET-positive tumors.
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
Conference Coverage
Pembro/chemo combo fails to improve event-free survival in head and neck cancer
Some trends favored chemoradiation plus pembrolizumab over chemoradiation alone, but KEYNOTE-412 failed to meet primary endpoint.
Conference Coverage
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
Nirogacestat has shown a significant improvement in progression-free survival and also a reduction in symptoms and better quality of life.
From the Journals
Nearly 30% of U.S. cancer deaths linked to smoking
Getting more people to screen for lung cancer in the United States is also important, given that only 6.6% of eligible people in 2019 received...
Feature
At-home test for oral/throat cancer launched in U.S.
It is not covered by medical insurance, and is not approved by the Food and Drug Administration.